| Symbol | AMRN |
|---|---|
| Name | AMARIN CORP PLC\UK |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2, None None |
| Telephone | 353 1 6699 020 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000897448 |
| Description | None |
Fishman Peter L. 🟡 adjusted position in 3.7K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $15.94 Transaction Date: Jul 01, 2026 | Filing ID: 304914
Read moreKeenan David Paul 🟡 adjusted position in 5.5K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $15.94 Transaction Date: Jul 01, 2026 | Filing ID: 304912
Read moreKetchum Steven B 🟡 adjusted position in 5.5K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $15.94 Transaction Date: Jul 01, 2026 | Filing ID: 304911
Read moreProvoost Jonathan 🟡 adjusted position in 6.1K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $15.94 Transaction Date: Jul 01, 2026 | Filing ID: 304910
Read moreBerg Aaron 🟡 adjusted position in 9.3K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $16.35 Transaction Date: Jun 26, 2026 | Filing ID: 290834
Read moreAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Read moreNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Read more(30% Negative) AMARIN CORP PLC\UK (AMRN) Reports Q2 2026 Financial Results
Read more